The cross-sectional relationship between body dysmorphic disorder and perfectionism: a meta-analysis
Abstract
Perfectionism has been theoretically implicated in the development and maintenance of body dysmorphic disorder (BDD), but a quantitative synthesis of its cross-sectional relationship with BDD symptom severity is lacking. The present meta-analysis therefore examines the strength and consistency of this relationship across existing studies. A random-effects meta-analysis of 34 studies comprising a total of 13 107 participants was conducted. Studies were included if they assessed BDD symptoms and perfectionism using validated instruments. Subgroup analyses were used to examine perfectionism dimensions, sample characteristics, and diagnostic subtypes. Partial correlations controlling for depression were examined. The results revealed a moderate and statistically significant correlation between BDD symptoms and perfectionism (r = .32, 95% CI [0.28, 0.36]). The association remained stable across age groups, sample types, and genders, and was comparable in individuals with muscle dysmorphia (r = .34). A separate meta-analysis focusing on individuals with elevated BDD symptoms yielded a comparable effect size (r = .35, 95% CI [0.22, 0.47]). Controlling for depressive symptoms attenuated the relationship, indicating that part of the association may be attributable to shared depressive symptomatology. Significant heterogeneity (I² = 81%) and evidence of publication bias were detected, although the findings were comparable across several sensitivity analyses. The results highlight the…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 13 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.